Skip to main content

Table 4 Association of change in cell counts (pre- to post-chemotherapy) and with post-chemotherapy frailty

From: The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy

Change in cell counts

Post-chemotherapy frailty score: β (SE)

Neutrophils

0.026**

     

(0.010)

     

Lymphocytes

 

0.042

    
 

(0.032)

    

Monocytes

  

0.019

   
  

(0.074)

   

NLR

   

0.032***

  
   

(0.009)

  

LMR

    

− 0.003*

 
    

(0.002)

 

WBC

     

0.024**

     

(0.009)

Baseline frailty

0.318***

0.312***

0.308***

0.332***

0.321***

0.297***

(0.046)

(0.047)

(0.047)

(0.047)

(0.048)

(0.045)

Age 50–64

0.216*

0.224*

0.215*

0.210*

0.211*

0.212*

(0.115)

(0.115)

(0.115)

(0.116)

(0.119)

(0.111)

Age 65+

0.312*

0.323**

0.301*

0.270

0.332**

0.240

(0.160)

(0.161)

(0.161)

(0.164)

(0.167)

(0.156)

White (yes = 1)

0.104

0.145

0.083

0.091

0.143

0.036

(0.176)

(0.177)

(0.174)

(0.179)

(0.183)

(0.169)

Married (yes = 1)

− 0.331***

− 0.322***

− 0.328***

− 0.281**

− 0.268**

− 0.311***

(0.118)

(0.120)

(0.120)

(0.121)

(0.124)

(0.116)

Some college or above = 1

0.152

0.136

0.113

0.204

0.143

0.185

(0.123)

(0.123)

(0.123)

(0.125)

(0.127)

(0.118)

Constant

1.444***

1.462***

1.520***

1.296***

1.350***

1.564***

(0.230)

(0.233)

(0.228)

(0.236)

(0.239)

(0.223)

Observations

459

459

461

439

427

508

R-squared

0.135

0.123

0.115

0.147

0.126

0.115

  1. Linear regression models were used to evaluate the association between cell counts and frailty, controlling for age (below 50, 50–64 versus ≥ 65 years), race (white versus non-white), marital status (married/long term relationship versus others), and education (≥ some college versus ≤ high school)
  2. NLR neutrophil to lymphocyte ratio, LMR lymphocyte to monocyte ratio
  3. *Significant at 10%; **significant at 5%; ***significant at 1%